Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ADIL 
Adial Pharmaceuticals Inc (ADIL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ADIL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -73.41% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.31M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Price to earnings Ratio - | 1Y Target Price 6.5 | ||
Volume (30-day avg) 1543252 | Beta 1.13 | 52 Weeks Range 0.61 - 3.10 | Updated Date 04/1/2025 |
52 Weeks Range 0.61 - 3.10 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.72 |
Earnings Date
Report Date 2025-03-31 | When After Market | Estimate -0.33 | Actual -0.15 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -105.88% | Return on Equity (TTM) -323.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 562404 | Price to Sales(TTM) - |
Enterprise Value 562404 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.49 | Shares Outstanding 6574590 | Shares Floating 6146385 |
Shares Outstanding 6574590 | Shares Floating 6146385 | ||
Percent Insiders 1.4 | Percent Institutions 9.58 |
Analyst Ratings
Rating 4.33 | Target Price 7.5 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Adial Pharmaceuticals Inc
Company Overview
History and Background
Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for diseases related to addictions. Founded in 2010, the company's lead product candidate is AD04, a therapeutic agent for treating Alcohol Use Disorder (AUD). Significant milestones include the advancement of AD04 through clinical trials and strategic partnerships.
Core Business Areas
- Therapeutic Development: Adial focuses on developing and commercializing therapies for treating addictions, particularly AUD.
- Clinical Trials: The company conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
Leadership and Structure
The company's leadership team includes the CEO, CMO, and CFO, along with a board of directors. The organizational structure is typical of a clinical-stage biopharmaceutical company, with departments focused on research, development, clinical operations, and regulatory affairs.
Top Products and Market Share
Key Offerings
- AD04: AD04 is Adial's lead product candidate for the treatment of Alcohol Use Disorder (AUD). It is designed to target genetically-defined subpopulations of AUD patients. Market share data is not currently available as AD04 is not yet approved. Competitors include pharmaceutical companies with approved AUD treatments, such as naltrexone and acamprosate, and companies developing novel AUD therapies.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with significant research and development costs. The market for addiction therapies is growing due to increasing awareness of addiction and the need for more effective treatments.
Positioning
Adial is positioned as a company developing a personalized medicine approach to treating AUD, targeting genetically-defined subpopulations. Its competitive advantage lies in its unique targeting mechanism and potential for improved efficacy in specific patient groups.
Total Addressable Market (TAM)
The TAM for AUD treatments is estimated to be in the billions of dollars annually. Adial aims to capture a significant portion of this market by offering a more targeted and potentially more effective treatment option. The global AUD market is estimated at over $4 billion and is expected to grow. Adial is targeting a specific genetic subtype, aiming for a substantial share within that segment.
Upturn SWOT Analysis
Strengths
- Targeted therapeutic approach
- Proprietary technology
- Experienced management team
- Lead candidate in late-stage clinical development
Weaknesses
- Limited financial resources
- Reliance on single lead candidate
- High regulatory risk
- Lack of commercial infrastructure
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into other addiction therapies
- Increasing awareness of AUD and need for treatment
Threats
- Clinical trial failures
- Regulatory delays or rejection
- Competition from established AUD treatments
- Generic entry
- Economic downturn impacting R&D funding
Competitors and Market Share
Key Competitors
- VIVUS (VVUS)
- Alkermes (ALKS)
- Orexo AB (ORX.ST)
Competitive Landscape
Adial's competitive advantage lies in its personalized medicine approach. However, it faces competition from established pharmaceutical companies with approved AUD treatments. Adial's success depends on demonstrating superior efficacy and safety compared to existing therapies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Adial's growth has been primarily in terms of advancing AD04 through clinical trials. Financial growth has been limited due to the lack of commercialized products.
Future Projections: Future growth is dependent on the successful development and commercialization of AD04. Analyst estimates are highly variable and depend on clinical trial outcomes. The success of AD04 in late-stage clinical trials is crucial for positive future projections.
Recent Initiatives: Recent initiatives include ongoing clinical trials of AD04, efforts to secure partnerships and collaborations, and presentations at scientific conferences.
Summary
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company with a unique personalized medicine approach to treating Alcohol Use Disorder. The company's success is highly dependent on the outcome of clinical trials for its lead product candidate, AD04. While its targeted approach offers a potential competitive advantage, it faces significant risks related to clinical development, regulatory approval, and competition from established treatments. The company needs to secure additional funding and partnerships to successfully navigate the regulatory landscape and commercialize its product.
Similar Companies
CRBP
Corbus Pharmaceuticals Holding
CRBP
Corbus Pharmaceuticals Holding
CYTH
Cyclo Therapeutics Inc
CYTH
Cyclo Therapeutics Inc
VTVT
vTv Therapeutics Inc
VTVT
vTv Therapeutics Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on available information and may be subject to change. Investment in clinical-stage biopharmaceutical companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adial Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Glen Allen, VA, United States | ||
IPO Launch date 2018-07-30 | CEO, President & Director Mr. Cary John Claiborne MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.adial.com |
Full time employees 5 | Website https://www.adial.com | ||
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.